Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 16/9/2019
SIETES contiene 92806 citas

 
 
 1 a 20 de 1135 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet 2019:29 de agosto. [Ref.ID 103167]
2.Enlace a cita original Cita con resumen
Savolainen-Peltonen H, Rahkola-Soisalo P, Hoti F, Vattulainen P, Gissler M, Ylikorkala O, Mikkola TS. Use of postmenopausal hormone therapy and risk of Alzheimer’s disease in Finland: nationwide case-control study. BMJ 2019;364:6 de marzo. [Ref.ID 103059]
3. Cita con resumen
Baladé Martínez L, Montero Corominas D, Macías Saint-Gerons D. Uso del tratamiento hormonal sustitutivo en España: tendencias en el período 2000-2014. Med Clin (Barc) 2016;147:287-92. [Ref.ID 100772]
4.Tiene citas relacionadas Cita con resumen
Davis C, Lexchin J, Jefferson T, Gotzsche P, McKee M. "Adaptive pathways” to drug authorisation: adapting to industry?. BMJ 2016;354:i4437. [Ref.ID 100602]
5.Tiene citas relacionadas
Willett WC. Mediterranean diet and fracture risk. JAMA Intern Med 2016;176:652-3. [Ref.ID 100258]
6.Tiene citas relacionadas Cita con resumen
Haring B, Crandall CJ, Wu C, LeBlanc ES, Shikanty JM, Carbone L, Orchard T, Thomas F, Wactawaski-Wende J, Li W, Cauley JA, Wassertheil-Smoller S. Dietary patterns and fractures in postmenopausal women: results from the Women's Health Initiative. JAMA Intern Med 2016;176:645-52. [Ref.ID 100257]
7. Cita con resumen
Hodis HN, Mack WJ, Henderson VW, Shoupe D, Budoff MJ, Hwang-Levine J, Li Y, Feng M, Dustin L, Kono N, Stanczyk FZ, Selzer RH, Azen SP, ELITE Research Group. Vascular effects of early versus late postmenopausal treatment with estradiol. N Engl J Med 2016;374:1221-31. [Ref.ID 100167]
8. Cita con resumen
Anónimo. Traitement hormonal substitutif de la ménopause: cancers de l'ovaire. Prescrire 2015;35:671. [Ref.ID 99718]
9. Cita con resumen
Anónimo. Incontinences urinaires d'origine médicamenteuse. Prescrire 2015;35:271-4. [Ref.ID 99126]
10. Cita con resumen
Collaborative Group on Epidemiological Studies of Ovarian Cancer. Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies. Lancet 2015;385:1835-42. [Ref.ID 99038]
11. Cita con resumen
Joffe HV, Guthrie KA, LaCroix AZ, Reed SD, Ensrud KE, Manson JE, Newton KM, Freeman EW, Anderson GL, Larson JC, Hunt J, Shifren J, Rexrode KM, Caan B, Stemfeld B, Carpenter JS, Cohen L. Low-dose estradiol and the serotonin-norepinephrine reuptake inhibitor venlafaxine for vasomotor symptoms: a randomized clinical trial. JAMA Intern Med 2014;174:1058-66. [Ref.ID 97792]
12. Cita con resumen
Roth JA, Etzioni R, Waters TM, Pettinger M, Rossouw JE, Anderson GL, Chlebowski RT, Manson JE, Hlatky M, Johnson KC, Ramsey SD. Economic return from the Women's Health Initiative estrogen plus progestin clinical trial. A modeling study. Ann Intern Med 2014;160:594-602. [Ref.ID 97572]
13. Cita con resumen
Schufelt CL, Merz CN, Prentice RL, Pettinger MB, Rossouw JE, Aroda VR, Kaunitz AM, Lakshminarayan K, Martin LW, Phillips LS, Manson JE. Hormone therapy and cardiovascular disease risk: dose, route of delivery, and risk of cardiovascular events in women: findings from the Women's Health Initiative Observational Study. Menopause 2014;21:260-6. [Ref.ID 97430]
14. Cita con resumen
Oskarsson V, Orsini N, Sadr-Azodi O, Wolk A. Postmenopausal hormone replacement therapy and risk of acute pancreatitis: a prospective cohort study. Can Med Assoc J 2014;186:338-44. [Ref.ID 97097]
15. Cita con resumen
Smith NL, Blondon M, Wiggins KL, Harrington LB, van Hylckama Vlieg A, Floyd JS, Hwang M, Bis JC, McKnight B, Rice KM, Lumley T, Rosendaal FR, Heckbert SR, Psaty BM. Lower risk of cardiovascular events in postmenopausal women taking oral estradiol compared with oral conjugated equine estrogens. JAMA Intern Med 2014;174:25-35. [Ref.ID 97020]
16.
Hellfritzsch Simonsen M, Erichsen R, Frøslev T, Rungby J, Toft Sørensen H. Postmenopausal estrogen therapy and risk of gallstone disease: a population-based case-control study. Drug Saf 2013;2013:1189-97. [Ref.ID 96692]
17.Tiene citas relacionadas
Grodstein F. Hormone therapy in younger women and cognitive health. JAMA Intern Med 2013;173:1437-8. [Ref.ID 95978]
18.Tiene citas relacionadas Cita con resumen
Espeland MA, Shumaker SA, Leng I, Manson JE, Brown CM, LeBland ES, Vaughan L, Robinson J, Rapp SR, Goveas JS, Lane D, Wactawski-Wende J, Stefanick ML, Li W, Resnick SM, WHIMSY Study Group. Long-term effects on cognitive function of postmenopausal hormone therapy prescribed to women aged 50 to 55 years. JAMA Intern Med 2013;173:1429-36. [Ref.ID 95976]
19. Cita con resumen
Chlebowski RT, Manson JE, Anderson GL, Cauley JA, Aragaki AK, Stefanick ML, Lane DS, Johnson KC, Wactawski-Wende J, Chen C, Qi L, Yasmeen S, Newcomb PA, Prentice RL. Estrogen plus progestin and breast cancer incidence and mortality in the Women's Health Initative observational study. J Natl Cancer Inst 2013;105:526-35. [Ref.ID 95454]
20. Cita con resumen
Svensson S, Menkes DB, Lexchin J. Surrogate outcomes in clinical trials: a cautionary tale. JAMA Intern Med 2013;173:611-2. [Ref.ID 95286]
Seleccionar todas
 
 1 a 20 de 1135 siguiente >>